73 related articles for article (PubMed ID: 21742581)
1. Phenotypic changes in a laboratory-derived ertapenem-resistant Escherichia coli strain.
Santos KV; Carvalho MA; Martins WA; Andrade HM; Veloso LC; Coutinho SC; Bahia JL; Andrade JP; Apolonio AC; Diniz CG; Nicoli JR; Farias LM
J Chemother; 2011 Jun; 23(3):135-9. PubMed ID: 21742581
[TBL] [Abstract][Full Text] [Related]
2. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
Tängdén T; Adler M; Cars O; Sandegren L; Löwdin E
J Antimicrob Chemother; 2013 Jun; 68(6):1319-26. PubMed ID: 23478794
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam.
dos Santos KV; Diniz CG; Veloso Lde C; de Andrade HM; Giusta Mda S; Pires Sda F; Santos AV; Apolônio AC; de Carvalho MA; Farias Lde M
Res Microbiol; 2010 May; 161(4):268-75. PubMed ID: 20381611
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.
Ungphakorn W; Tängdén T; Sandegren L; Nielsen EI
J Antimicrob Chemother; 2016 Sep; 71(9):2521-33. PubMed ID: 27330073
[TBL] [Abstract][Full Text] [Related]
5. Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae.
Szabó D; Silveira F; Hujer AM; Bonomo RA; Hujer KM; Marsh JW; Bethel CR; Doi Y; Deeley K; Paterson DL
Antimicrob Agents Chemother; 2006 Aug; 50(8):2833-5. PubMed ID: 16870780
[TBL] [Abstract][Full Text] [Related]
6. Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008-2009).
Hawser SP; Bouchillon SK; Hoban DJ; Badal RE; Hackel MA; Lascols CA; Villegas MV; Rossi F
J Chemother; 2012 Feb; 24(1):6-11. PubMed ID: 22546718
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
Valéria Dos Santos K; Roque DE Carvalho MA; Amancio Martins W; Coutinho SC; Bahia JL; Lopes DE Andrade JP; Morais Apolonio AC; Cara DC; Galuppo Diniz C; Nicoli JR; DE Macedo Farias L
J Chemother; 2010 Aug; 22(4):259-63. PubMed ID: 20685630
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
Hawser SP; Bouchillon SK; Lascols C; Hackel M; Hoban DJ; Badal RE; Cantón R
Clin Microbiol Infect; 2012 Mar; 18(3):253-9. PubMed ID: 21635662
[TBL] [Abstract][Full Text] [Related]
10. Ertapenem resistance of Escherichia coli.
Lartigue MF; Poirel L; Poyart C; Réglier-Poupet H; Nordmann P
Emerg Infect Dis; 2007 Feb; 13(2):315-7. PubMed ID: 17479901
[TBL] [Abstract][Full Text] [Related]
11. Emergence of imipenem resistance in clinical Escherichia coli during therapy.
Oteo J; Delgado-Iribarren A; Vega D; Bautista V; Rodríguez MC; Velasco M; Saavedra JM; Pérez-Vázquez M; García-Cobos S; Martínez-Martínez L; Campos J
Int J Antimicrob Agents; 2008 Dec; 32(6):534-7. PubMed ID: 18775649
[TBL] [Abstract][Full Text] [Related]
12. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
Mody RM; Erwin DP; Summers AM; Carrero HA; Selby EB; Ewell AJ; Moran KA
Ann Clin Microbiol Antimicrob; 2007 Jun; 6():6. PubMed ID: 17553151
[TBL] [Abstract][Full Text] [Related]
13. Outer membrane vesicles from β-lactam-resistant Escherichia coli enable the survival of β-lactam-susceptible E. coli in the presence of β-lactam antibiotics.
Kim SW; Park SB; Im SP; Lee JS; Jung JW; Gong TW; Lazarte JMS; Kim J; Seo JS; Kim JH; Song JW; Jung HS; Kim GJ; Lee YJ; Lim SK; Jung TS
Sci Rep; 2018 Mar; 8(1):5402. PubMed ID: 29599474
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
Alhambra A; Cuadros JA; Cacho J; Gómez-Garcés JL; Alós JI
J Antimicrob Chemother; 2004 Jun; 53(6):1090-4. PubMed ID: 15117925
[TBL] [Abstract][Full Text] [Related]
16. Refractory vertebral osteomyelitis due to CTX-M-14-producing Escherichia coli at ertapenem treatment in a patient with a coexisting urinary tract infection caused by the same pathogen.
Lee CH; Su LH; Lin WC; Tang YF; Liu JW
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e183-6. PubMed ID: 19800278
[TBL] [Abstract][Full Text] [Related]
17. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013.
Lob SH; Kazmierczak KM; Badal RE; Hackel MA; Bouchillon SK; Biedenbach DJ; Sahm DF
Antimicrob Agents Chemother; 2015; 59(6):3606-10. PubMed ID: 25801558
[TBL] [Abstract][Full Text] [Related]
18. Discordance in the minimal inhibitory concentrations of ertapenem for Enterobacter cloacae: Vitek 2 system versus Etest and agar dilution methods.
Pailhoriès H; Cassisa V; Lamoureux C; Chesnay A; Lebreton C; Lemarié C; Kempf M; Mahaza C; Joly-Guillou ML; Eveillard M
Int J Infect Dis; 2014 Jan; 18():94-6. PubMed ID: 24183718
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
20. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
